Care of patients with systemic immunoglobulin light chain (AL) amyloidosis has undergone transformative changes, leading to marked, steady progress in outcomes for patients over the past four decades.

Interviewer: Amyloidosis is a rare and possibly debilitating disease, which affects about 4,000 people a year in the United States. If left untreated, the disease can cause severe organ damage, so ...

First central lab in EU to perform this blood-based assay under IVDR/LDT regulations, supporting inclusion and exclusion criteria in Alzheimer’s clinical trials Achieving IVDR validation for the ...

The Amyloidosis Program at University of Utah Health and Huntsman Cancer Institute is one of the few programs in the United States specifically designed to treat amyloidosis and provide ...

Transthyretin amyloidosis, also called ATTR amyloidosis, is associated with accumulation of ATTR amyloid deposits in the heart and commonly manifests as progressive cardiomyopathy. Patisiran, an RNA ...

The bar for quality in cardiac amyloid radionuclide imaging is very high because the results from a single imaging scan can impact the diagnosis and treatment of patients with a devastating disease.” ...

Amyloid heart disease occurs when amyloid fibrils build up in the heart, making it more difficult for the heart to pump blood around the body. Eventually, this can lead to heart failure. People can ...